The development of BCR-ABL-targeting tyrosine kinase inhibitors (TKIs), such as imatinib, has revolutionized the treatment of CML patients [3–5]; however, resistance to TKIs remains a major obstacle to successful CML treatment. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.